Infectious Disease

A fatal pediatric measles case in Los Angeles highlights the urgent need for MMR vaccination to protect vulnerable children from severe complications.

According to phase 3 trial results, Pfizer-BioNTech’s LP.8.1-adapted COVID-19 vaccine demonstrated significant immune responses in older adults and individuals at high risk for severe COVID-19.

Florida's Surgeon General's plan to eliminate school vaccine mandates raises concerns about measles outbreaks and declining vaccination rates.

The 21-valent pneumococcal conjugate vaccine (PCV21) elicited favorable immunogenicity and safety in infants and toddlers who were coadministered common pediatric vaccines, such as the measles-mumps-rubella vaccine.

RSV vaccination shows promise in reducing cardiorespiratory hospitalizations among older adults, highlighting potential heart and lung health benefits.

A single dose of an RSV vaccine significantly reduces hospitalization risk for older adults, offering protection for 2 seasons against severe infections.

Vaccination is vital for adults with heart disease to prevent severe respiratory illnesses like RSV, influenza, and COVID-19, enhancing overall health outcomes.

Patients with severe COVID-19 who tested positive for Streptococcus pneumoniae had higher mortality rates.

The FDA's approvals follow new COVID-19 guidance announced by the commissioner of the agency in May 2025, focusing future approvals on older adults.

RSV causes a significant burden of acute respiratory infections in older adults.

Patients in an outpatient oncology unit expressed willingness to receive a pneumococcal or influenza vaccine from a pharmacist if offered.

RSVpreF was well tolerated in nonpregnant and pregnant individuals aged 18 years and older.

The implementation of nonpharmaceutical measures during the COVID-19 pandemic reduced transmission of Streptococcus pneumoniae, a key bacterium that causes pneumococcal disease.

Many adults remain unaware of HPV's cancer risks, highlighting the urgent need for increased awareness.

IDSA updated cUTI guidelines for men and women emphasize antibiotic selection, transition to oral therapy, and optimal treatment duration.

RSV vaccination rates among older adults remain low despite new vaccines, highlighting disparities in uptake and the need for targeted outreach.

Pharmacists play a crucial role in improving vaccination rates among patients with cancer, addressing barriers, and enhancing patient education in oncology care.

In a phase 3 trial, V116 demonstrated significant immunogenicity in older adults who had not before received a pneumococcal vaccination.

RSV poses a serious risk to older adults in long-term care, highlighting the need for effective outbreak management and infection control strategies.

WHO reclassifies hepatitis D as carcinogenic, urging global action to combat viral hepatitis and reduce liver cancer risk.

Continuing a trend observed since the end of the COVID-19 pandemic, vaccine coverage among kindergartners declined in the 2024-2025 school year, according to CDC data.

Ivermectin shows promise in reducing malaria cases, enhancing vector control, and highlighting pharmacists' vital roles in public health strategies.

RSV hospitalization in older adults links to increased cardiovascular events, highlighting the need for vigilant monitoring and vaccination strategies.

RSV outbreaks pose significant risks globally, highlighting the urgent need for targeted vaccination and treatment strategies to protect vulnerable populations.

Cephalosporins are commonly prescribed in the outpatient setting; understanding differences among them is important for pharmacists.

Immense burden is laid upon patients with cancer who are infected with COVID-19, as they are at higher risk of experiencing cancer treatment disruptions and severe illness that necessitates hospitalization.

Immunocompromised patients, especially transplant recipients, face heightened RSV risks, leading to severe infections and complications.

The FDA recently approved gepotidacin oral tablets for the treatment of uncomplicated urinary tract infections (UTIs).

Researchers unveil compounds that enhance cell death and boost antiviral responses, offering hope against RSV and other viral infections.